Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy

ABSTRACT Background Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. Methods Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m2 on days 1 and 8) and DOC (100 mg/m2 on day 8), were retrospectiv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2016-09, Vol.63 (9), p.1552-1556
Hauptverfasser:	Lee, Jun Ah, Jeon, Dae-Geun, Cho, Wan Hyeong, Song, Won Seok, Yoon, Hoi Soo, Park, Hyeon Jin, Park, Byung Kiu, Choi, Hyoung Soo, Ahn, Hyo Seop, Lee, Ji Won, Yoo, Keon Hee, Sung, Ki Woong, Koo, Hong Hoe, Kang, Hyoung Jin, Park, Kyung Duk, Shin, Hee Young, Koh, Kyung-Nam, Im, Ho Joon, Seo, Jong Jin, Lim, Yeon Jung, Baek, Hee Jo, Kook, Hoon
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Neoplasms - drug therapy Bone Neoplasms - mortality Child Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives docetaxel Female gemcitabine Hematology Humans Male Oncology osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - mortality Pediatrics recurrent refractory Retrospective Studies Taxoids - administration & dosage Taxoids - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!